# Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers

> **NCT05604690** · PHASE1 · COMPLETED · sponsor: **Intravacc B.V.** · enrollment: 40 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Avacc 10
- **COMBINATION_PRODUCT:** Outer Membrane Vesicles (OMV) : OMV alone in vehicle
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05604690
- **Lead sponsor:** Intravacc B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-03
- **Primary completion:** 2023-08-09
- **Final completion:** 2024-01-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05604690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05604690, "Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05604690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*